| User's Publication |
|
22337
Osako R, Hayano A, Kawaguchi A, Yamanaka R.
Single-cell RNA-seq reveals diverse molecular signatures associated with Methotrexate resistance in primary central nervous system lymphoma cells
J Neurooncol
2024
2024 Dec 5
PubMed ID: 39636551
DOI: 10.1007/s11060-024-04893-y
|
|
21284
Suzuki K, Yamamoto J, Toh K, Miyaoka R.
5‑aminiolevulinic acid induces a radiodynamic effect with enhanced delayed reactive oxygen species production under hypoxic conditions in lymphoma cells: An in vitro study.
Exp Ther Med
2023
26(1):360
PubMed ID: 37324514
DOI: 10.3892/etm.2023.12059
|
|
16945
Yano H, Fujiwara Y, Horlad H, Pan C, Kai K, Niino D, Ohsawa K, Higashi M, Nosaka K, Okuno Y, Tamaru JI, Mukasa A, Matsuoka M, Komohara Y.
Blocking cholesterol efflux mechanism is a potential target for antilymphoma therapy
Cancer Sci
2022
113(6):2129-2143
PubMed ID: 35343027
DOI: 10.1111/cas.15349
|
|
20208
Takashima Y, Kawaguchi A, Fukai J, Iwadate Y, Kajiwara K, Hondoh H, Yamanaka R.
Survival prediction based on the gene expression associated with cancer morphology and microenvironment in primary central nervous system lymphoma.
PLoS One
2021
16(6):e0251272
PubMed ID: 34166375
DOI: 10.1371/journal.pone.0251272
|
|
9864
Yasuo Takashima, Azusa Hayano, Ryuya Yamanaka
Metabolome Analysis Reveals Excessive Glycolysis via PI3K/AKT/mTOR and RAS/MAPK Signaling in Methotrexate-Resistant Primary CNS Lymphoma-Derived Cells
Clin Cancer Res
2020
26(11):2754-2766
PubMed ID: 32108030
DOI: 10.1158/1078-0432.CCR-18-3851
|
|
11997
Muta H, Sugita Y, Furuta T, Shiimura Y, Ohshima K, Nakashima K, Sato K, Morioka M, Abe H, Nozawa T, Fujii Y, Kakita A.
Expression of the ghrelin/growth hormone secretagogue receptor axis and its functional role in promoting tumor growth in primary central nervous system lymphomas.
Neuropathology
2020
PubMed ID: 31925841
DOI: 10.1111/neup.12634
|
|
13062
Takashima Y, Hamano M, Fukai J, Iwadate Y, Kajiwara K, Kobayashi T, Hondoh H, Yamanaka R.
GSEA-assisted gene signatures valid for combinations of prognostic markers in PCNSL.
Sci Rep
2020
PubMed ID: 32439996
DOI: 10.1038/s41598-020-65463-6
|
|
13099
Fujimoto K, Shinojima N, Hayashi M, Nakano T, Ichimura K, Mukasa A.
Histone deacetylase inhibition enhances the therapeutic effects of methotrexate on primary central nervous system lymphoma.
Neurooncol Adv
2020
PubMed ID: 32793886
DOI: 10.1093/noajnl/vdaa084
|
|
11518
Hayano A, Takashima Y, Yamanaka R.
Cell-type-specific sensitivity of bortezomib in the methotrexate-resistant primary central nervous system lymphoma cells.
Int. J. Clin. Oncol.
2019
PubMed ID: 30993483
DOI: 10.1007/s10147-019-01451-9
|
|
11849
Mulazzani M, Huber M, Borchard S, Langer S, Angele B, Schuh E, Meinl E, Dreyling M, Birnbaum T, Straube A, Koedel U, von Baumgarten L.
APRIL and BAFF: novel biomarkers for central nervous system lymphoma.
J Hematol Oncol
2019
PubMed ID: 31615554
DOI: 10.1186/s13045-019-0796-4
|
|
6897
Takashima Y, Yoshimura T, Kano Y, Hayano A, Hondoh H, Ikenaka K, Yamanaka R.
Differential expression of N-linked oligosaccharides in methotrexate-resistant primary central nervous system lymphoma cells.
BMC Cancer
2019
19(1):910
PubMed ID: 31510952
DOI: 10.1186/s12885-019-6129-8
|
|
11125
Miyasato Y, Takashima Y, Takeya H, Yano H, Hayano A, Nakagawa T, Makino K, Takeya M, Yamanaka R, Komohara Y.
The expression of PD-1 ligands and IDO1 by macrophage/microglia in primary central nervous system lymphoma.
J Clin Exp Hematop
2018
58(2):95-101
PubMed ID: 29998979
DOI: 10.3960/jslrt.18001
|
|
11858
Shinojima N, Fujimoto K, Makino K, Todaka K, Yamada K, Mikami Y, Oda K, Nakamura K, Jono H, Kuratsu JI, Nakamura H, Yano S, Mukasa A.
Clinical significance of polyglutamylation in primary central nervous system lymphoma.
Acta Neuropathol Commun
2018
PubMed ID: 29475458
DOI: 10.1186/s40478-018-0522-4
|
|
10300
Takahashi Y, Sawada T, Akahane T, Kawase Y, Ikeda H, Makino K, Nakamura H, Hide T, Yano S, Hashimoto N, Kamada H.
Monocyte chemoattractant protein 1 expression and proliferation in primary central nervous system lymphoma.
Oncol Lett
2017
14:264-270
PubMed ID: 28693163
DOI: 10.3892/ol.2017.6122
|
|
14351
Ma C, Horlad H, Pan C, Yano H, Ohnishi K, Fujiwara Y, Matsuoka M, Lee A, Niidome T, Yamanaka R, Takeya M, Komohara Y.
Stat3 inhibitor abrogates the expression of PD-1 ligands on lymphoma cell lines
J Clin Exp Hematop
2017
57(1):21-25
PubMed ID: 28496056
DOI: 10.3960/jslrt.17006
|
|
7310
Mizowaki T, Sasayama T, Tanaka K, Mizukawa K, Takata K, Nakamizo S, Tanaka H, Nagashima H, Nishihara M, Hirose T, Itoh T, Kohmura E.
STAT3 activation is associated with cerebrospinal fluid interleukin-10 (IL-10) in primary central nervous system diffuse large B cell lymphoma.
J. Neurooncol.
2015
124:165-74
PubMed ID: 26080800
DOI: 10.1007/s11060-015-1843-9
|
Back
Top
CELL BANK Website
